Impel Pharmaceuticals Inc. Stock Price, News & Analysis

Impel Pharmaceuticals (NASDAQ: IMPL) announced key findings from the Phase 3 STOP 301 trial at the 64th AHS Scientific Meeting. An oral presentation highlighted that early response to Trudhesa nasal spray, a treatment for migraines, predicts ongoing effectiveness. New analyses also reported long-term patient-reported benefits, such as reduced disability and headache days, with Trudhesa. The drug, utilizing Impel’s Precision Olfactory Delivery technology, aims to offer rapid, effective relief without the side effects of traditional treatments. The study supports Trudhesa's potential as a viable option for migraine sufferers.

Impel Pharmaceuticals (NASDAQ: IMPL) announced that CEO Adrian Adams will present a company overview at the JMP Securities Life Sciences Conference on June 15, 2022, at 2:00 p.m. ET in New York. The event will focus on the company’s development of transformative therapies targeting high unmet medical needs, particularly in the central nervous system. A live webcast will be available on their Investors page, with a replay accessible for 90 days. Impel’s notable product is Trudhesa, a nasal spray for migraine treatment.

Impel Pharmaceuticals (NASDAQ: IMPL) reported a strong Q1 2022 with Trudhesa® achieving 111% growth in total prescriptions compared to Q4 2021. The company generated $1.8 million in net product revenues, an increase from zero in 2021. Research and Development expenses decreased to $3.7 million, while Selling, General and Administrative costs rose significantly to $19.8 million due to commercialization efforts. A $100 million financing agreement with Oaktree Capital extends the cash runway into 2024. The company plans to initiate the INP105 study for Autism Spectrum Disorder in Q2 2022.

Impel Pharmaceuticals (NASDAQ: IMPL) is set to present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 5:00 p.m. ET in Miami. CEO Adrian Adams will provide a company overview, highlighting Impel's focus on transformative therapies for central nervous system diseases. The event will feature a live webcast accessible through their Investor section. Impel is known for its Trudhesa® nasal spray for migraine treatment and is developing INP105 for agitation in autism patients.

Impel Pharmaceuticals Inc. (NASDAQ: IMPL) will host a live webcast on May 16, 2022, at 8:30 a.m. ET to report its Q1 2022 financial results and provide a business update. The call can be accessed via phone or through a live webcast on their investor website. Impel focuses on developing therapies for unmet medical needs, particularly in the central nervous system. Their approved product, Trudhesa™, is a nasal spray for migraine treatment, and they are developing additional treatments for autism-related agitation and Parkinson’s disease.

Impel Pharmaceuticals, formerly Impel NeuroPharma, celebrates its one-year anniversary as a publicly traded company at the Nasdaq closing bell ceremony. The name change reflects a strategic shift, expanding its focus beyond central nervous system disorders to other areas of high unmet medical needs. The company emphasizes the potential of its Precision Olfactory Delivery (POD®) technology, which aims to enhance drug absorption via the upper nasal space. Trudhesa®, its approved migraine treatment, marks a significant milestone in this evolution. Stock trading will continue under the ticker IMPL.

Impel NeuroPharma (NASDAQ: IMPL) celebrates its first anniversary as a public company by ringing the Nasdaq closing bell on April 25, 2022. CEO Adrian Adams highlighted the company's successful launch of Trudhesa®, a nasal spray for treating acute migraines. The product has exceeded early performance expectations, and Impel has secured financing to sustain operations into 2024. The company is committed to addressing unmet medical needs in the central nervous system and is poised for a transformative year in 2022.

Impel NeuroPharma (NASDAQ: IMPL) announced that Adrian Adams, Chairman and CEO, will present a company overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 1:30 p.m. ET. The presentation will focus on transformative therapies for central nervous system diseases, highlighting Impel's Precision Olfactory Delivery technology and its approved product Trudhesa for migraine treatment. A live webcast will be available on their website, with a replay offered for 90 days.

Impel NeuroPharma (NASDAQ: IMPL) reported strong growth for Trudhesa™, achieving a 157% increase in prescriptions since year-end 2021, totaling approximately 11,000 prescriptions. The company exceeded its fourth-quarter guidance of 3,000-4,000 prescriptions, generating over 4,200. Impel secured a $100 million royalty and debt agreement, extending its cash runway into 2024. Despite net losses of $24.7 million (Q4) and $76.7 million (full year), the company is optimistic about 2022, projecting Trudhesa prescriptions between 70,000 and 85,000.